您的位置: 首页 > 农业专利 > 详情页

METHOD FOR EMERGENCY PREVENTION AND TREATMENT OF ACUTE RADIATION SICKNESS (VERSIONS)
专利权人:
Federalnoe gosudarstvennoe byudzhetnoe uchrezhdenie nauki "Uralskij nauchno-prakticheskij tsentr radiatsionnoj meditsiny Federalnogo mediko-biologicheskogo agentstva" (FGBUN UNPTS RM FMBA Rossii)
发明人:
Akleev Aleksandr Vasilevich (RU),Аклеев Александр Васильевич (RU),Pryakhin Evgenij Aleksandrovich (RU),Пряхин Евгений Александрович (RU),Tryapitsyna Galina Aleksandrovna (RU),Тряпицына Галина Александ
申请号:
RU2018127107
公开号:
RU0002699040C1
申请日:
2018.07.23
申请国别(地区):
RU
年份:
2019
代理人:
摘要:
FIELD: medicine.SUBSTANCE: group of inventions refers to medicine, namely to radiation medicine, and can be used for prevention and treatment of acute radiation sickness (ARS). First version of the method involves administering a liposomal preparation containing recombinant human alpha-protein (rhAFP) in amount of 0.1–1.0 mg/ml intravenously once after irradiation in a dose of up to 10 mg/kg of body weight in terms of rhAFP or same dose according to scheme: immediately after irradiation and 1, 3, 5, 7 days after irradiation. Second version of the method involves administering a liposomal preparation containing a recombinant human granulocyte colony-stimulating factor (rhGCSF) in amount of 0.004–0.06 mg/ml intravenously once immediately after irradiation in a dose of up to 0.2 mg/kg of body weight in terms of rhGCSF or in the same dose according to the scheme: immediately after irradiation and 1, 3, 5, 7 days after irradiation. In the third version, the acute prevention and treatment of acute radiation sickness is accompanied by administering a liposomal preparation containing rhAFP in amount of 0.1–1.0 mg/ml and rhGCSF in amount of 0.004–0.06 mg/ml. This preparation is administered intravenously once immediately after irradiation in dose of 10 mg/kg of body weight in terms of rhAFP and up to 0.2 mg/kg of body weight in terms of rhGCSF or in the same doses according to the scheme: immediately after irradiation and after 1, 3, 5, 7 days after irradiation.EFFECT: use of the inventions enables the prevention and treatment of ARS by regulating growth, development and programmed death of hematopoietic stem cells, differentiation and activation of immune cells, stimulation of proliferation and maturation of granulocyte-containing blood leukocytes, as well as repair of radiation-damaged cell membranes.3 cl, 4 tbl, 2 exГруппа изобретений относится к медицине, а именно к радиационной медицине, и может быть использована для профилактики и лечения острой лучевой болезни (ОЛБ).
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充